- LBT Innovations (LBT) has sold two of its APAS Independence instruments for use in a Sonic Healthcare (SHL) subsidiary laboratory in the U.K.
- The instruments were sold through LBT’s s joint venture company, Clever Culture Systems, to Health Services Laboratory for use at its Halo Facility in London
- The deal marks the first U.K sales for the Australian medical technology company, with the instruments set to perform screening of high volume urine and MRSA specimens and at the facility
- In addition, the data generated from the clinical evaluation of MRSA completed by HSL has been accepted as a poster presentation for the European Congress of Clinical Microbiology and Infectious Diseases conference in July
- LBT Innovations shares are up 12.7 per cent following the announcement, trading at 8 cents per share
LBT Innovations (LBT) has sold two of its APAS Independence instruments for use in a Sonic Healthcare (SHL) subsidiary laboratory in the U.K.
The instruments were sold through LBT’s s 50 per cent owned joint venture company, Clever Culture Systems, to Health Services Laboratory to be used in its Halo Facility in London.
The deal marks the first U.K sales for the Australian medical technology company.
According to LBT, the laboratory is part of a public-private partnership and is a flagship U.K. laboratory and centre of excellence for The Doctors Laboratory, a subsidiary of Sonic Healthcare.
The device APAS Independence devices are set to perform screening of high volume urine and MRSA specimens and at the facility and will sit alongside the already installed BD Kiestra Total Lab Automation (TLA) solution.
In addition, the data generated from the clinical evaluation of MRSA completed by HSL has been accepted as a poster presentation for the European Congress of Clinical Microbiology and Infectious Diseases conference to be held virtually in July 2021.
LBT explains the APAS device uses artificial intelligence to screen culture plates and divides them into three categories: negatives, positives, and those to be reviewed.
Health Services Laboratory’s Head of Department Alan Spratt said the technology exceeded their expectations during testing.
While LBT Innovation’s Managing Director Brent Barnes said the team was thrilled with the arrangement.
“This is a demonstration of the positive experience we have consistently seen from laboratories who have trialled our technology,” he commented.
“As a technology leader in microbiology in the UK, this sale is also another key step to us building awareness and early adoption of the APAS technology in the UK marketplace,” he added.
LBT Innovations shares are up 12.7 per cent following the announcement, trading at 8 cents per share at 11:34 am AEST.